GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16489 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Giovanni Antonio Silverii und 5 weiteren Autor:innen. Beteiligte Einrichtung: AOU Careggi, Diabetology Unit - Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Neoplasms, Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
To assess if there is a difference in the oncogenic risk between GLP‐1 RA and comparators in randomized controlled trials. Materials and Methods A meta‐analysis of randomized controlled trials comparing GLP‐1RA to any comparators for diabetes and/or obesity, lasting at least 52 weeks. The endpoints included the incidence of overall cancers and single malignancies.
Results
Fifty trials were included. GLP‐1RA treatment was not associated with a significant difference in risk for overall cancer (MH‐OR 1.05, 95% confidence interval [CI] [0.98, 1.13]). Uterine cancer was significantly reduced in the GLP‐1RA arm in trials performed in subjects with obesity (MH‐OR 0.24, 95% CI [0.06, 0.94]), but not in those aimed at diabetes treatment (MH‐OR 0.92, [0.58, 1.47]). We detected an increase in the risk for thyroid cancer (MH‐OR 1.55, [1.05, 2.27]), more evident in longer‐term trials, and in the risk for colorectal cancer (MH‐OR 1.27 [1.03, 1.57]), which, conversely, was significant only in shorter‐term trials. No significant difference in the risk was detected for any other cancer.
Conclusions
GLP‐1 RA do not appear to produce an effect on most malignancies in clinical trials. A reduction of very close obesity‐associated cancers seems possible, whereas a risk signal for thyroid cancer was observed, prompting the need for further specific studies. On the other hand, the small increase observed in colorectal cancer in shorter‐term trials may be the effect of a disproportionate increase in diagnostic procedures in the GLP‐1 RA arm, because of the suspicion raised by common side effects of GLP‐1 RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AOU Careggi, Diabetology Unit - Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Florence, Italy.
- Diabetology Unit, AOU Careggi, Florence, Italy.
ORCID-Profile: Giovanni Antonio Silverii, Matteo Monami, Edoardo Mannucci
Zitieren
APA
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025). GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16489
Vancouver
Silverii GA, Marinelli C, Bettarini C, Del Vescovo GG, Monami M, Mannucci E. GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16489
BibTeX
@article{Silverii2025,
author = {Silverii, Giovanni Antonio and Marinelli, Christian and Bettarini, Costanza and Del Vescovo, Gloria Giovanna and Monami, Matteo and Mannucci, Edoardo},
title = {GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16489}
}
EUVIMED